8AON image
Deposition Date 2022-08-08
Release Date 2023-08-02
Last Version Date 2025-02-19
Entry Detail
PDB ID:
8AON
Keywords:
Title:
Oxidoreductase fragment of human QSOX1 in complex with a Fab fragment of a humanized anti-QSOX1 antibody
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.10 Å
R-Value Free:
0.25
R-Value Work:
0.19
R-Value Observed:
0.20
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Heavy chain
Chain IDs:B
Chain Length:225
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Oxidoreductase fragment of human QSOX1
Chain IDs:A (auth: B00A)
Chain Length:244
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Light chain
Chain IDs:C
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Computational optimization of antibody humanness and stability by systematic energy-based ranking.
Nat Biomed Eng 8 30 44 (2024)
PMID: 37550425 DOI: 10.1038/s41551-023-01079-1

Abstact

Conventional methods for humanizing animal-derived antibodies involve grafting their complementarity-determining regions onto homologous human framework regions. However, this process can substantially lower antibody stability and antigen-binding affinity, and requires iterative mutational fine-tuning to recover the original antibody properties. Here we report a computational method for the systematic grafting of animal complementarity-determining regions onto thousands of human frameworks. The method, which we named CUMAb (for computational human antibody design; available at http://CUMAb.weizmann.ac.il), starts from an experimental or model antibody structure and uses Rosetta atomistic simulations to select designs by energy and structural integrity. CUMAb-designed humanized versions of five antibodies exhibited similar affinities to those of the parental animal antibodies, with some designs showing marked improvement in stability. We also show that (1) non-homologous frameworks are often preferred to highest-homology frameworks, and (2) several CUMAb designs that differ by dozens of mutations and that use different human frameworks are functionally equivalent.

Legend

Protein

Chemical

Disease

Primary Citation of related structures